References
- Adlin E. V., Marks A. D., Channick B. J. Spironolactone and hydrochlorothízide in essential hypertension. Arch. intern. Med. 1972; 130: 855
- Anderson G. H., Dalakos Th. G., Elias A. Diuretic therapy and response of essential hypertension to Saralasin. Ann. intern. Med. 1977; 87: 183
- Bevegard S., Castenfors J., Danielson M. The effect of four months treatment with spironolactone on systemic blood pressure, cardiac output and plasma renin activity in hypertensive patients. Acta med. scand. 1977; 202: 373
- Darracott Vaughan E., Jr, Laragh J. H., Gavras I., Buhler F. R., Gavras H., Brunner H. R., Baer L. Volume factor in low and normal renin essential hypertension. Amer. J. Cardiol. 1973; 32: 523
- Distler A., Keim H. J., Philipp Th., Phillipi A., Walter U., Wolff H. P. Exchangeable sodium, plasma volume, and the effects of spironolactone in hypertensive patients with suppressed plasma renin. Europ. J. clin. Invest. 1973; 3: 224
- Falch D. K., Norman N. Evaluation of a computerized technique for determination of cardiac output and central circulation times using gamma camera and 113mIndium. Scand. J. clin. Lab. Invest. 1974; 34: 207
- Falch D. K., Norman N. The cardiac response to a small i.v. dose of dihydralazine, a safe drug for diagnostic tests?. Acta med. scand., 203: 433–1978
- Falch D. K., ødegaard A. E., Norman N. Renal plasma flow and cardiac output during hydralazine and propranolol treatment in essential hypertension. Scand. J. clin. Lab. Invest. 1978; 38: 143
- Falch D. K., Strømme S. B. Pulmonary blood volume and interventricular circulation time in physically trained and untrained subjects. Eur. J. appl. Physiol. (In press.)
- Kert M. J., Tarr L. W., Franklin S., Gold E., Okun R., Maxwell M. Experience with the use of an aldosterone antagonist in selected hypertensive patients. Angiology 1972; 23: 617
- Kincaid-Smith P., Faug P., Laver M. C. A new look at the treatment of severe hypertension. Clin. Sci. molec. Med. 1973; 45: 75s
- Kremer D., Beevers D. G., Brown J. J., Davies D. L., Ferris J. B., Fraser R., Lever A. F., Robertson J. I.S. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. Clin. Sci. molec. Med. 1973; 45: 213s
- Norman N. Effective plasma flow of the inidvidual kidney. Determination on the basis of the [131I]hippuran renogram. Scand. J. clin. Lab. Invest. 1972; 30: 395
- Norman N., Sundsfjord J. A., Stiris G. Effective renal plasma flow (ERPF) of the individual kidney and renal venous renin activity (RVRA) determined simultaneously before and after the administration of dihydralazine in renovascular hypertension. Scand. J. clin. Lab. Invest. 1975; 35: 219
- Solheim S. B., Sundsfjord J. A., Gierzendanner Z. The effect of spironolactone (Aldactone®) and methyldopa in low and normal renin hypertension. Acta med. scand. 1975; 197: 451
- Sundsfjord J. A. Radioimmunological determination of plasma renin activity during menstrual cycle and during acute progesterone administration. Acta Endocr. (Kbh.) 1971; 67: 174
- Sundsfjord J. A., Aakvaag A. Variations in plasma aldosterone and plasma renin activity throughout the menstrual cycle, special reference to the pre-ovulatory period. Acta Endocr. (Kbh.) 1973; 73: 499
- Sundsfjord J. A., Marton J., Jørgensen H., Aakvaag A. Reduced aldosterone secretion during spironolactone treatment in primary aldosteronism: report of case. J. clin. Endocr. Metab. 1974; 39: 734